What is UroGen Pharma's zusduri — revenue?

UroGen Pharma (URGN) reported zusduri — revenue of $29.25M in Q1 2026.

What does zusduri — revenue mean?

This metric represents the total gross revenue generated from the sale of the Zusduri product line, excluding any applicable sales taxes or similar government-assessed levies. It serves as a primary indicator of the commercial adoption and market penetration of this specific therapeutic offering within the company's portfolio. Tracking this revenue stream allows stakeholders to evaluate the product's contribution to overall top-line growth and its trajectory within the competitive oncology landscape.

UroGen Pharma URGN Zusduri — Revenue

Similar metrics at other companies

PTCTUpstaza And Kebilidi — Revenue

$9.59M+10.8%

AVPTDE — Revenue

$16.4M+33.5%

LNTHNon Us — Revenue

$22.91M+52.6%

MBLYDE — Revenue

$77M+4.1%

LNTHProduct — Revenue

$369.85M+0.8%

LNTHDefinity — Revenue

$84.63M+6.8%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's zusduri — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's zusduri — revenue?: UroGen Pharma (URGN) reported zusduri — revenue of $29.25M in Q1 2026.
What does zusduri — revenue mean?: This metric represents the total gross revenue generated from the sale of the Zusduri product line, excluding any applicable sales taxes or similar government-assessed levies. It serves as a primary indicator of the commercial adoption and market penetration of this specific therapeutic offering within the company's portfolio. Tracking this revenue stream allows stakeholders to evaluate the product's contribution to overall top-line growth and its trajectory within the competitive oncology landscape.